Rituximab for the treatment of the skin manifestations of dermatomyositis: a report of 3 cases.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 17097377.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Three patients suffering from classic dermatomyositis (juvenile and adult-onset) with prominent recalcitrant skin manifestations are described. All patients demonstrated good control of muscle symptoms on immunosuppressive medications, but their cutaneous disease persisted despite treatment with at least 4 different systemic treatments and topical agents. They were given rituximab, a monoclonal anti-CD20 antibody, achieving a response with minimal side effects. We document our experience with this medication for the cutaneous lesions of dermatomyositis.
Medical subject headings
- Antibodies, Monoclonal
- Dermatomyositis
- Immunosuppressive Agents